Taken all together, these data indicated that therapeutic dosages of aspirin not only neutralized the pro-tumorigenic effects of IL-6 stimulation in mouse hepatocytes in vivo, but also increased the p53-related anti-tumor potential in unstimulated control hepatocytes. The gene discussed is TP53; the disease is neoplasm.